Trials / Active Not Recruiting
Active Not RecruitingNCT05210283
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,017 (actual)
- Sponsor
- Exact Sciences Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRD | ctDNA MRD test |
Timeline
- Start date
- 2021-12-15
- Primary completion
- 2027-05-15
- Completion
- 2027-05-15
- First posted
- 2022-01-27
- Last updated
- 2026-01-12
Locations
32 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05210283. Inclusion in this directory is not an endorsement.